GlassScriptPhysician profile
Jesse Frye
NPI 1457810327
$1,309.06
in general payments reported to CMS, 2019-2025
12 companies · $407 in 2025
The $407 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $63.65 · 2023: $288 · 2024: $550 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $428.66 | 2024-2025 | Impella |
| Pfizer INC. | $239.13 | 2022-2024 | |
| Chiesi USA, INC. | $201.52 | 2023-2025 | Kengreal, Cleviprex |
| Actelion Pharmaceuticals US, INC. | $109.90 | 2025 | |
| Medtronic, INC. | $94.84 | 2025 | Cobalt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.00 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $46.16 | 2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $38.01 | 2023-2025 | Wainua, Farxiga |
| Janssen Scientific Affairs, LLC | $29.47 | 2024 | Xarelto |
| Terumo Medical Corporation | $22.13 | 2023 | Angio-Seal |
| Merck Sharp & Dohme LLC | $14.93 | 2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Frye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.